United States Biotechnology & Medical Research

Chemomab Therapeutics Ltd (CMMB)

Track

Track

Chemomab Therapeutics experienced two insider trading transactions within the last ninety days, both involving Neil Harris Cohen. These activities consisted exclusively of sales totaling 6,516.40 USD. This selling pattern follows a period where the stock price appreciated by 75.5 percent, occurring prior to the most recent September 2026 results financiers report.
Ticker: CMMB Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Chemomab Therapeutics Ltd. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
1.7
Cohen Neil Harris Non-Executive Director
Transaction date
Sale
Price
105.40
Quantity 60,342 -18.9%
Value US$1,024,499
1.7
Cohen Neil Harris Non-Executive Director
Transaction date
Sale
Price
173.07
Quantity 71,989 -6.9%
Value US$3,301,394
2.8
Mor George Adi Chief Scientific Officer Executive Director
Transaction date
Planned sale
Price
5.03
Quantity 6,100 -2.4%
Value US$30,663
2.8
Mor George Adi Chief Scientific Officer Executive Director
Transaction date
Planned sale
Price
5.03
Quantity 7,700 -2.4%
Value US$38,706
3.9
OrbiMed Israel GP Ltd. Large shareholder
Transaction date
Sale
Price
4.51
Quantity 70,524 -3.1%
Value US$318,063
3.9
OrbiMed Israel GP Ltd. Large shareholder
Transaction date
Sale
Price
3.34
Quantity 266,376 -10.3%
Value US$889,696
1.7
Cohen Neil Harris Non-Executive Director
Transaction date
Sale
Price
2.00
Quantity 2,409 -19.4%
Value US$4,818
2.8
Mor George Adi Chief Scientific Officer Executive Director
Transaction date
Sale
Price
2.08
Quantity 257,248 -50.0%
Value US$536,311
2.8
Mor George Adi Chief Scientific Officer Executive Director
Transaction date
Sale
Price
2.08
Quantity 324,775 -50.0%
Value US$677,091
1.4
Maryles Joel Michael Non-Executive Director
Transaction date
Purchase
Price
2.76
Quantity 33 +2.4%
Value US$91
1.4
Maryles Joel Michael Non-Executive Director
Transaction date
Purchase
Price
2.89
Quantity 400 +40.0%
Value US$1,156
1.7
Cohen Neil Harris Non-Executive Director
Transaction date
Purchase
Price
3.19
Quantity 2,000 +19.2%
Value US$6,380
1.4
Maryles Joel Michael Non-Executive Director
Transaction date
Purchase
Price
4.36
Quantity 500 +100.0%
Value US$2,180
1.4
Maryles Joel Michael Non-Executive Director
Transaction date
Purchase
Price
4.32
Quantity 500 +inf%
Value US$2,160
2.3
Marvin Donald Executive VP, CFO & COO Officer
Transaction date
Purchase
Price
3.25
Quantity 250 +14.3%
Value US$812
2.3
Marvin Donald Executive VP, CFO & COO Officer
Transaction date
Purchase
Price
3.30
Quantity 250 +16.7%
Value US$825
2.3
Marvin Donald Executive VP, CFO & COO Officer
Transaction date
Purchase
Price
4.20
Quantity 250 +20.0%
Value US$1,050
2.3
Marvin Donald Executive VP, CFO & COO Officer
Transaction date
Purchase
Price
4.10
Quantity 250 +25.0%
Value US$1,025
2.3
Marvin Donald Executive VP, CFO & COO Officer
Transaction date
Purchase
Price
3.90
Quantity 250 +33.3%
Value US$975
2.3
Marvin Donald Executive VP, CFO & COO Officer
Transaction date
Purchase
Price
3.98
Quantity 250 +100.0%
Value US$995
2.3
Marvin Donald Executive VP, CFO & COO Officer
Transaction date
Purchase
Price
4.00
Quantity 250 +inf%
Value US$1,000
1.4
Pfost Dale R Chief Executive Officer Executive Director
Transaction date
Purchase
Price
3.97
Quantity 700 +38.9%
Value US$2,779
1.4
Pfost Dale R Chief Executive Officer Executive Director
Transaction date
Purchase
Price
3.98
Quantity 1,800 +inf%
Value US$7,164
1.7
Cohen Neil Harris Non-Executive Director
Transaction date
Purchase
Price
4.56
Quantity 2,000 +23.8%
Value US$9,120
1.7
Cohen Neil Harris Non-Executive Director
Transaction date
Purchase
Price
4.30
Quantity 2,000 +31.2%
Value US$8,600
1.7
Cohen Neil Harris Non-Executive Director
Transaction date
Purchase
Price
4.20
Quantity 2,000 +45.4%
Value US$8,400
0.9
Darvish Nissim Non-Executive Director
Transaction date
Purchase
Price
4.28
Quantity 1,200 +inf%
Value US$5,136
1.7
Cohen Neil Harris Non-Executive Director
Transaction date
Purchase
Price
7.43
Quantity 2,000 +83.0%
Value US$14,860
1.7
Cohen Neil Harris Non-Executive Director
Transaction date
Purchase
Price
41.51
Quantity 2,409 +inf%
Value US$99,998
1.3
THIEL PETER Large shareholder
Transaction date
Purchase
Price
0.00
Quantity 230,536
Value US$0
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-09-01 2026-08-28 S Sale
1.7
Cohen Neil Harris
Non-Executive Director
60,342 -18.9%
105.40
US$1,024,499 		60,342 -18.9% 105.40 US$1,024,499
2026-09-01 2026-08-27 S Sale
1.7
Cohen Neil Harris
Non-Executive Director
71,989 -6.9%
173.07
US$3,301,394 		71,989 -6.9% 173.07 US$3,301,394
2024-09-12 2024-09-12 PrS Proposed sale
3.9
OrbiMed Israel Partners Limited Partnership

Owner
88,377
185.83
US$796,561 		88,377 185.83 US$796,561
2023-01-05 2023-01-03 PlS Planned sale
2.8
Mor George Adi

Chief Scientific Officer

Executive Director
6,100 -2.4%
5.03
US$30,663 		6,100 -2.4% 5.03 US$30,663
2023-01-05 2023-01-03 PlS Planned sale
2.8
Mor George Adi

Chief Scientific Officer

Executive Director
7,700 -2.4%
5.03
US$38,706 		7,700 -2.4% 5.03 US$38,706
2023-01-05 2023-01-03 S Sale
3.9
OrbiMed Israel GP Ltd.
Large shareholder
70,524 -3.1%
4.51
US$318,063 		70,524 -3.1% 4.51 US$318,063
2023-01-05 2023-01-03 S Sale
3.9
OrbiMed Israel GP Ltd.
Large shareholder
266,376 -10.3%
3.34
US$889,696 		266,376 -10.3% 3.34 US$889,696
2022-11-18 2022-11-16 S Sale
1.7
Cohen Neil Harris
Non-Executive Director
2,409 -19.4%
2.00
US$4,818 		2,409 -19.4% 2.00 US$4,818
2022-11-17 2022-11-16 S Sale
2.8
Mor George Adi

Chief Scientific Officer

Executive Director
257,248 -50.0%
2.08
US$536,311 		257,248 -50.0% 2.08 US$536,311
2022-11-17 2022-11-16 S Sale
2.8
Mor George Adi

Chief Scientific Officer

Executive Director
324,775 -50.0%
2.08
US$677,091 		324,775 -50.0% 2.08 US$677,091
2022-05-25 2022-05-24 B Purchase
1.4
Maryles Joel Michael
Non-Executive Director
33 +2.4%
2.76
US$91 		33 +2.4% 2.76 US$91
2022-05-25 2022-05-24 B Purchase
1.4
Maryles Joel Michael
Non-Executive Director
400 +40.0%
2.89
US$1,156 		400 +40.0% 2.89 US$1,156
2022-05-19 2022-05-18 B Purchase
1.7
Cohen Neil Harris
Non-Executive Director
2,000 +19.2%
3.19
US$6,380 		2,000 +19.2% 3.19 US$6,380
2022-03-21 2022-03-18 B Purchase
1.4
Maryles Joel Michael
Non-Executive Director
500 +100.0%
4.36
US$2,180 		500 +100.0% 4.36 US$2,180
2022-03-21 2022-03-18 B Purchase
1.4
Maryles Joel Michael
Non-Executive Director
500 +inf%
4.32
US$2,160 		500 +inf% 4.32 US$2,160
2022-06-21 2022-03-16 B Purchase
2.3
Marvin Donald

Executive VP, CFO & COO

Officer
250 +14.3%
3.25
US$812 		250 +14.3% 3.25 US$812
2022-06-21 2022-03-16 B Purchase
2.3
Marvin Donald

Executive VP, CFO & COO

Officer
250 +16.7%
3.30
US$825 		250 +16.7% 3.30 US$825
2022-03-21 2022-03-14 B Purchase
2.3
Marvin Donald

Executive VP, CFO & COO

Officer
250 +20.0%
4.20
US$1,050 		250 +20.0% 4.20 US$1,050
2022-03-21 2022-03-14 B Purchase
2.3
Marvin Donald

Executive VP, CFO & COO

Officer
250 +25.0%
4.10
US$1,025 		250 +25.0% 4.10 US$1,025
2022-03-21 2022-03-14 B Purchase
2.3
Marvin Donald

Executive VP, CFO & COO

Officer
250 +33.3%
3.90
US$975 		250 +33.3% 3.90 US$975
2022-03-21 2022-03-14 B Purchase
2.3
Marvin Donald

Executive VP, CFO & COO

Officer
250 +100.0%
3.98
US$995 		250 +100.0% 3.98 US$995
2022-03-21 2022-03-14 B Purchase
2.3
Marvin Donald

Executive VP, CFO & COO

Officer
250 +inf%
4.00
US$1,000 		250 +inf% 4.00 US$1,000
2022-03-15 2022-03-14 B Purchase
1.4
Pfost Dale R

Chief Executive Officer

Executive Director
700 +38.9%
3.97
US$2,779 		700 +38.9% 3.97 US$2,779
2022-03-15 2022-03-14 B Purchase
1.4
Pfost Dale R

Chief Executive Officer

Executive Director
1,800 +inf%
3.98
US$7,164 		1,800 +inf% 3.98 US$7,164
2022-03-15 2022-03-14 B Purchase
1.7
Cohen Neil Harris
Non-Executive Director
2,000 +23.8%
4.56
US$9,120 		2,000 +23.8% 4.56 US$9,120
2022-03-15 2022-03-14 B Purchase
1.7
Cohen Neil Harris
Non-Executive Director
2,000 +31.2%
4.30
US$8,600 		2,000 +31.2% 4.30 US$8,600
2022-03-15 2022-03-14 B Purchase
1.7
Cohen Neil Harris
Non-Executive Director
2,000 +45.4%
4.20
US$8,400 		2,000 +45.4% 4.20 US$8,400
2022-03-14 2022-03-11 B Purchase
0.9
Darvish Nissim
Non-Executive Director
1,200 +inf%
4.28
US$5,136 		1,200 +inf% 4.28 US$5,136
2021-12-08 2021-12-06 B Purchase
1.7
Cohen Neil Harris
Non-Executive Director
2,000 +83.0%
7.43
US$14,860 		2,000 +83.0% 7.43 US$14,860
2021-03-26 2021-03-16 B Purchase
1.7
Cohen Neil Harris
Non-Executive Director
2,409 +inf%
41.51
US$99,998 		2,409 +inf% 41.51 US$99,998
2021-03-18 2021-03-16 B Purchase
1.3
THIEL PETER
Large shareholder
230,536
0.00
US$0 		230,536 0.00 US$0
Explore more

More insider trading research around Chemomab Therapeutics Ltd

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America